Evofem Biosciences, Inc.
For the period ended Dec 31, 2025. Filed Mar 11, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 11, 2026
EVFM$0.48-23.4%Stored close · as of Aug 10, 2022
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Financial Statements and Supplementary Data
Item 8. Financial Statements and Supplementary Data.
The consolidated financial statements and the report of our independent registered public accounting firm required pursuant to this item are included in this Annual Report on Form 10-K beginning on page F-1.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.